Predictive Factors for Response to Treatment in Aplastic Anemia with HIV: A Narrative Review

Article · September 2024

CITATIONS
0

READS
18

3 authors, including:

Emmanuel Ifeanyi Obeagu
Africa University
2,100 PUBLICATIONS **36,090** CITATIONS
SEE PROFILE

Getrude Uzoma Obeagu
Kampala International University
649 PUBLICATIONS **18,724** CITATIONS
SEE PROFILE

Elite Journal of Nursing and Health Sciences. Volume 2 Issue 9(2024), Pp. 1-20 https://epjournals.com/journals/EJNHS

Predictive Factors for Response to Treatment in Aplastic Anemia with HIV: A Narrative Review

*Emmanuel Ifeanyi Obeagu, Getrude Uzoma Obeagu[2] and Sussanah Henry Edoho[2]

[1]Department of Medical Laboratory Science, Kampala International University, Ishaka, Uganda.

[2]School of School of Nursing Science, Kampala International University, Ishaka, Uganda.

*Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161

Abstract

Aplastic anemia (AA) presents a significant clinical challenge in patients with HIV, where the interplay between the hematologic disorder and the viral infection complicates treatment and impacts outcomes. This review explores the predictive factors influencing treatment response in AA patients with HIV, focusing on how various elements, including HIV disease status, bone marrow function, hematologic parameters, and therapeutic strategies, affect patient outcomes. Key factors such as the stage of HIV infection, the choice of antiretroviral therapy (ART), and the presence of comorbidities are crucial in determining the effectiveness of AA treatments. Factors such as immunologic responses, the presence of autoantibodies, and genetic and epigenetic influences also play a critical role in predicting treatment outcomes. Additionally, adherence to prescribed therapies and management of comorbid conditions are pivotal in achieving favorable results. By examining these predictive factors, the review aims to provide a comprehensive understanding of how to improve treatment strategies and patient care.

Keywords: *Aplastic anemia, HIV, treatment response, predictive factors, bone marrow failure*

Introduction

Aplastic anemia (AA) is a severe hematologic condition characterized by the failure of the bone marrow to produce sufficient blood cells, leading to pancytopenia—reduction in red blood cells, white blood cells, and platelets.[1] This condition is particularly challenging in the context of HIV infection, where the interaction between HIV-related factors and AA complicates diagnosis, treatment, and management.[2] The overlap of these two serious conditions necessitates a nuanced understanding of the predictive factors that influence treatment response and outcomes.[3] HIV infection can exacerbate the severity of AA by further impairing bone marrow function and

Citation: Obeagu EI, Obeagu GU, Edoho SH. Predictive Factors for Response to Treatment in Aplastic Anemia with HIV: A Narrative Review**.** Elite Journal of Nursing and Health Science, 2024; 2(9):1-21

immune system regulation.[4] The virus itself and the resultant immune dysfunction contribute to the complexity of managing AA in HIV-positive patients.[5] The interplay between HIV and AA is multifaceted, involving the impact of HIV on bone marrow health, the influence of antiretroviral therapy (ART) on hematologic function, and the increased risk of complications and infections.[6] The management of AA in HIV-infected individuals requires a careful balance between addressing the hematologic disorder and effectively controlling HIV. Effective antiretroviral therapy (ART) is essential for suppressing viral replication and improving immune function, which in turn can influence the response to AA treatment.[7-8] However, some ART regimens have been associated with myelosuppressive effects that can exacerbate AA, making the selection of appropriate antiretroviral drugs crucial in optimizing patient outcomes.[9] Predictive factors for treatment response in AA patients with HIV include baseline HIV disease status, such as viral load and CD4+ cell count, which are indicative of overall immune function and disease severity.[10] High CD4+ counts and undetectable viral loads generally correlate with better treatment responses, while advanced HIV with low CD4+ counts often complicate treatment and worsens outcomes. Therefore, managing HIV effectively is a key component in improving AA treatment responses.[11-12]

Hematologic parameters also play a significant role in predicting treatment outcomes. Initial blood cell counts, bone marrow cellularity, and erythropoietin levels provide insights into the severity of AA and the likelihood of a positive response to treatment.[13] Patients with more severe bone marrow suppression and lower initial blood cell counts may face a more challenging treatment course, necessitating tailored therapeutic strategies.[14] In addition to HIV and hematologic factors, immunologic aspects, such as the presence of autoantibodies and immune-mediated destruction of hematopoietic cells, influence treatment responses.[15] Autoimmune components can contribute to the severity of AA, and addressing these factors through immunosuppressive therapies may improve outcomes.[16] Identifying specific immunologic factors can help guide more targeted treatment approaches.[17] Comorbid conditions and overall health status also impact treatment efficacy. Opportunistic infections, liver and kidney dysfunction, and other chronic illnesses can complicate the management of AA and affect the response to treatment. Comprehensive care that addresses these comorbidities is crucial for optimizing treatment outcomes and minimizing complications.[18-19]

Aim

The aim of this narrative review is to critically evaluate and summarize the predictive factors for treatment response in patients with aplastic anemia (AA) co-infected with HIV.

Justification

Aplastic anemia (AA) is a rare and life-threatening condition that, when coupled with HIV infection, presents significant clinical challenges due to the interplay between bone marrow failure, immune dysfunction, and antiretroviral therapy (ART). While treatment strategies for AA in HIV-negative patients are well established, the same protocols may not yield optimal outcomes in HIV-positive patients due to the unique immunological and genetic factors influenced by the virus.

Identifying the predictive factors for treatment response in HIV-associated AA is essential to provide personalized and effective care. This review is justified because it addresses the lack of comprehensive guidance on treating AA in HIV-positive individuals, a population at higher risk for complications such as infections, ART toxicity, and immune suppression. Furthermore, this review will contribute to the ongoing efforts to optimize therapy, ensure better bone marrow recovery, and mitigate the long-term effects of both HIV and AA.

Review Methodology

Literature Search Strategy

A systematic literature search was conducted to identify relevant studies on predictive factors for treatment response in aplastic anemia (AA) among HIV-infected individuals. The search was performed in several electronic databases, including PubMed, Scopus, Web of Science, and Google Scholar. The keywords and phrases used in the search included "aplastica anemia," "HIV," "predictive factors," "treatment response," "immunosuppressive therapy," and "bone marrow transplantation." The search was limited to articles published in English between 2000 and 2024 to capture the most recent advancements in the field.

Inclusion and Exclusion Criteria

The inclusion criteria for the review comprised:

- Studies focusing on adult and pediatric patients with AA diagnosed alongside HIV infection.
- Articles that evaluated clinical, immunological, genetic, and treatment-related factors affecting treatment outcomes in HIV-associated AA.
- Both observational and interventional studies, including clinical trials and retrospective analyses.

The exclusion criteria included:

- Studies not specifically addressing HIV-infected individuals with AA.
- Reviews, editorials, and commentaries without original data.
- Articles published before 2000, as earlier studies may not reflect current practices and understanding of the disease.

Quality Assessment

The methodological quality of the included studies was assessed using appropriate tools depending on the study design. For observational studies, the Newcastle-Ottawa Scale (NOS) was utilized to evaluate the quality based on selection, comparability, and outcome assessment. For clinical trials, the Cochrane Risk of Bias tool was employed to evaluate the risk of bias in randomized controlled trials. Studies were classified as low, moderate, or high quality based on their scores.

Citation: Obeagu EI, Obeagu GU, Edoho SH. Predictive Factors for Response to Treatment in Aplastic Anemia with HIV: A Narrative Review**.** Elite Journal of Nursing and Health Science, 2024; 2(9):1-21

Ethical Considerations

As this review utilized previously published data and did not involve direct interaction with patients or human subjects, ethical approval was not required. However, the authors ensured that all included studies adhered to ethical standards in their respective research, particularly concerning patient consent and confidentiality.

HIV Disease Status

The status of HIV disease is a crucial predictive factor in the management and treatment response of aplastic anemia (AA). The progression of HIV infection, as reflected by viral load and CD4+ cell count, directly impacts the severity of AA and the effectiveness of its treatment. Understanding how these aspects of HIV disease influence AA outcomes can help tailor therapeutic strategies to improve patient prognosis.[20-21] Viral load, or the amount of HIV RNA in the blood, is a key indicator of HIV disease activity. Patients with high viral loads typically have more advanced HIV infection and a greater degree of immune system compromise.[22] High viral loads are associated with a greater risk of opportunistic infections, which can further complicate the management of AA and affect treatment response.[23] Effective viral suppression through antiretroviral therapy (ART) is essential for improving overall immune function and enhancing the likelihood of a positive response to AA treatment.[24] Patients with undetectable viral loads generally experience better outcomes, as effective HIV control helps stabilize the immune system and reduces the risk of secondary complications.[25] The CD4+ cell count is another critical marker of immune function and HIV disease progression. CD4+ cells are essential for coordinating the immune response, and a low CD4+ count indicates significant immunosuppression.[26] In the context of AA, a low CD4+ count can exacerbate bone marrow failure and increase susceptibility to infections and other complications. Patients with higher CD4+ counts typically have a more robust immune system and are better positioned to respond to AA treatments.[27] Monitoring CD4+ levels and managing HIV to maintain or improve these counts is crucial for optimizing the treatment of AA. The stage of HIV disease, categorized by the World Health Organization (WHO) or Centers for Disease Control and Prevention (CDC) classification systems, influences the management of AA. Advanced stages of HIV (e.g., AIDS) are associated with more severe immunosuppression and a higher risk of complications, which can complicate AA treatment. Early detection and management of HIV, along with maintaining an undetectable viral load and a stable CD4+ count, can help mitigate the impact of HIV on AA and improve treatment outcomes.[28-30]

Adherence to antiretroviral therapy is crucial for controlling HIV infection and managing AA. Non-adherence to ART can lead to viral rebound, increased disease progression, and exacerbation of AA. Ensuring adherence to prescribed ART regimens is essential for achieving viral suppression and supporting overall immune health. Regular monitoring of HIV adherence and providing support to address barriers to medication adherence can enhance treatment efficacy and improve outcomes in patients with AA.[31-32] While effective ART is critical for controlling HIV, some antiretroviral drugs, particularly older nucleoside reverse transcriptase inhibitors (NRTIs) like

zidovudine (AZT), are known to have myelosuppressive effects that can worsen AA. The choice of ART regimen should consider the potential hematologic side effects and aim to minimize the risk of further bone marrow suppression. Newer ART classes, such as integrase strand transfer inhibitors (INSTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs), generally have a lower risk of myelosuppression and may be preferred in managing AA patients.[33-34] HIV-infected patients with AA may also have co-infections or other comorbidities that impact treatment response. Co-infections such as tuberculosis, hepatitis B or C, and opportunistic infections can complicate the management of AA and influence the effectiveness of treatment. Comprehensive management of HIV and associated conditions is necessary to optimize AA treatment outcomes and improve patient health. Regular monitoring of HIV disease status, including viral load and CD4+ counts, is essential for guiding AA treatment. Adjustments to ART and AA management strategies should be based on the latest HIV disease markers and patient response. Collaborating with specialists in both HIV and hematology can ensure a coordinated approach to managing both conditions and optimizing treatment outcomes.[35-36]

Bone Marrow Function

Bone marrow function is a central determinant in the management and prognosis of aplastic anemia (AA), particularly in patients with HIV. The bone marrow's ability to produce adequate blood cells is crucial for maintaining hematologic health, and its dysfunction is a hallmark of AA. Bone marrow cellularity refers to the proportion of hematopoietic cells relative to the overall marrow space. In AA, there is a marked reduction in hematopoietic cells, leading to hypocellularity.[37] This reduced cellularity impairs the marrow's ability to produce adequate numbers of red blood cells, white blood cells, and platelets. Evaluating bone marrow cellularity through biopsy and aspiration provides important information about the severity of AA and helps guide treatment decisions. Patients with severe hypocellularity often face more challenging treatment scenarios and may require more intensive therapeutic approaches, such as stem cell transplantation or high-dose immunosuppressive therapy. HIV infection can further compromise bone marrow function through several mechanisms.[38-39] The virus itself may directly infect hematopoietic cells in the bone marrow, disrupting normal cell production. Additionally, the inflammatory cytokines associated with HIV infection can contribute to bone marrow suppression and exacerbate AA. Effective management of HIV is therefore crucial for mitigating its negative impact on bone marrow function and improving the response to AA treatments.[40]

Hematopoiesis, the process by which the bone marrow produces blood cells, can be disrupted in AA patients with HIV. HIV-related factors, such as immune dysregulation and chronic inflammation, can impair the normal differentiation and proliferation of hematopoietic stem cells. This disruption can lead to a more severe form of AA and complicate treatment responses. Addressing these issues through effective HIV management and targeted therapies can help restore normal hematopoiesis and improve treatment outcomes. Bone marrow biopsy and aspiration are critical diagnostic tools for assessing marrow function and guiding treatment decisions in AA. These procedures provide detailed information about marrow cellularity, the presence of dysplastic changes, and the extent of hematopoietic cell reduction. In HIV-infected patients, these

assessments can help differentiate between primary AA and secondary causes of bone marrow failure, such as HIV-related opportunistic infections or malignancies. Regular monitoring of bone marrow function through these techniques is essential for evaluating treatment efficacy and adjusting therapeutic strategies as needed.[41-42] The degree of bone marrow dysfunction influences the choice and intensity of AA treatments. Patients with severe bone marrow failure may benefit from more aggressive interventions, such as immunosuppressive therapy or hematopoietic stem cell transplantation. Conversely, those with less severe marrow involvement may respond well to less intensive treatments. Personalized treatment plans that consider the degree of bone marrow dysfunction and the impact of HIV-related factors can help optimize outcomes. Ongoing monitoring of bone marrow function is crucial for evaluating treatment response and making necessary adjustments. Regular assessments through bone marrow biopsy, blood counts, and other diagnostic tests provide valuable insights into the effectiveness of therapy and the progression of AA. Monitoring helps identify potential complications, such as progression to leukemia or other malignancies, which can influence treatment decisions. Supportive care plays a significant role in managing bone marrow dysfunction in AA patients with HIV. Measures such as blood transfusions, growth factors, and antibiotics can help manage the symptoms of AA and address complications associated with bone marrow failure. Supportive care also helps maintain patient quality of life and can be crucial for improving overall treatment outcomes.[43-44]

Hematologic Parameters

Hematologic parameters are crucial indicators of disease severity and treatment response in aplastic anemia (AA), particularly when complicated by HIV infection. These parameters provide essential information about the extent of bone marrow failure and the effectiveness of therapeutic interventions.

1. Red Blood Cell Counts

Red blood cell (RBC) counts are a fundamental measure in diagnosing and managing AA. In AA, the production of RBCs is significantly reduced, leading to anemia. Low RBC counts result in symptoms such as fatigue, pallor, and shortness of breath. Monitoring RBC levels helps assess the severity of anemia and gauge the effectiveness of treatment. In HIV-infected patients, anemia may be compounded by the effects of the virus on hematopoiesis and potential interactions with antiretroviral therapies. Regular evaluation of RBC counts is essential for managing anemia and adjusting treatment strategies as needed.[45]

2. White Blood Cell Counts

White blood cell (WBC) counts are another critical parameter in AA. AA typically leads to leukopenia, or a reduced number of white blood cells, which compromises the immune system and increases the risk of infections. In HIV-infected patients, leukopenia can be exacerbated by the virus's direct effects on hematopoietic cells and the immunosuppressive effects of certain antiretroviral drugs. Monitoring WBC counts helps assess the degree of immune system

compromise and informs decisions about prophylactic measures and antimicrobial therapy to prevent infections.[46]

3. Platelet Counts

Platelet counts are an important measure of bone marrow function and bleeding risk in AA. Thrombocytopenia, or a reduced platelet count, is common in AA and can lead to increased bleeding and bruising. In HIV-infected patients, the risk of bleeding may be further elevated due to the potential effects of HIV on platelet production and function. Regular monitoring of platelet counts is crucial for managing bleeding complications and determining the need for platelet transfusions or other therapeutic interventions.[47]

4. Bone Marrow Aspiration and Biopsy

Bone marrow aspiration and biopsy are key diagnostic tools for evaluating hematologic parameters and determining the extent of bone marrow involvement in AA. These procedures provide detailed information about marrow cellularity, the presence of dysplastic changes, and the degree of hematopoietic cell reduction. In HIV-infected patients, these assessments can help differentiate between primary AA and secondary causes of bone marrow failure, such as HIV-related opportunistic infections or malignancies. Results from these procedures guide treatment decisions and help monitor response to therapy.[48]

5. Erythropoietin Levels

Erythropoietin (EPO) is a hormone produced by the kidneys that stimulates red blood cell production in the bone marrow. In AA, EPO levels may be elevated as a compensatory response to anemia. Measuring EPO levels can provide insights into the underlying cause of anemia and help guide treatment decisions. In HIV-infected patients, EPO levels may be influenced by both the disease itself and the effects of ART. Evaluating EPO levels can help determine the need for erythropoiesis-stimulating agents or other interventions to manage anemia.[49]

6. Reticulocyte Count

The reticulocyte count reflects the production of new red blood cells by the bone marrow. In AA, reticulocyte counts are typically low, indicating impaired erythropoiesis. Monitoring reticulocyte counts can help assess the marrow's response to treatment and gauge the effectiveness of interventions aimed at stimulating red blood cell production. In HIV-infected patients, changes in reticulocyte counts can provide additional information about the impact of HIV and ART on bone marrow function.[50]

7. Immune Hematologic Parameters

In addition to basic blood counts, immune hematologic parameters such as the presence of autoantibodies and markers of immune dysregulation can influence treatment responses in AA. Autoantibodies, such as those targeting hematopoietic cells, may contribute to the development of AA and complicate treatment. Evaluating these parameters can help identify underlying immune-

mediated mechanisms and guide the use of immunosuppressive therapies or other targeted treatments.[51]

8. Impact of HIV on Hematologic Parameters

HIV infection can affect various hematologic parameters, leading to more complex management of AA. The virus's impact on bone marrow function, coupled with the potential myelosuppressive effects of ART, can result in more pronounced hematologic abnormalities. Comprehensive monitoring of hematologic parameters, along with effective HIV management, is essential for optimizing treatment outcomes and minimizing complications in AA patients with HIV.[52]

Antiretroviral Therapy Regimen

Antiretroviral therapy (ART) is a cornerstone of HIV management and plays a critical role in the treatment of HIV-infected patients with aplastic anemia (AA). The choice of ART regimen can influence both HIV control and the management of AA, impacting overall treatment outcomes and patient quality of life. ART regimens typically consist of a combination of antiretroviral drugs from different classes to effectively suppress HIV replication and prevent the development of drug resistance.[52] The primary classes of antiretroviral drugs include:

- **Nucleoside Reverse Transcriptase Inhibitors (NRTIs):** These drugs inhibit the reverse transcriptase enzyme, preventing the conversion of viral RNA into DNA. Examples include zidovudine (AZT) and tenofovir.
- **Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs):** NNRTIs bind directly to reverse transcriptase, inhibiting its activity. Examples include efavirenz and etravirine.
- **Protease Inhibitors (PIs):** These drugs inhibit the protease enzyme, preventing the maturation of viral particles. Examples include ritonavir and lopinavir.
- **Integrase Strand Transfer Inhibitors (INSTIs):** INSTIs block the integration of viral DNA into the host genome. Examples include raltegravir and dolutegravir.
- **Fusion Inhibitors:** These drugs prevent the fusion of the HIV virus with the host cell membrane. An example is enfuvirtide.
- **CCR5 Antagonists:** These drugs block the CCR5 receptor on the surface of CD4+ cells, preventing HIV entry. An example is maraviroc.

The choice of ART regimen for patients with AA should take into account the potential for drug-induced myelosuppression, which can exacerbate bone marrow failure and complicate the management of AA. Older NRTIs, such as zidovudine (AZT), are known to have myelosuppressive effects and can worsen anemia, neutropenia, and thrombocytopenia. Therefore, these drugs should be used cautiously in AA patients, and alternative agents with a lower risk of bone marrow toxicity may be preferred.[53] ART regimens can have varying effects on bone marrow function. For example, some drugs may have direct myelosuppressive effects, while others may contribute to

improvements in hematologic parameters through effective HIV control. Modern ART regimens, particularly those including INSTIs and newer NNRTIs, tend to have a more favorable side effect profile regarding bone marrow function compared to older regimens. Monitoring the impact of ART on bone marrow function is crucial for managing AA and optimizing treatment outcomes.[54] Patients with AA and HIV often require complex medication regimens, including treatments for both conditions. Drug interactions between ART and medications used to manage AA or associated complications must be carefully monitored. For instance, certain ART drugs can interact with medications used for supportive care, such as growth factors or immunosuppressive agents, potentially affecting their efficacy and safety. A thorough review of potential drug interactions and dose adjustments may be necessary to minimize adverse effects and optimize therapeutic outcomes.[55]

Adherence to ART is critical for effective HIV management and preventing the development of drug resistance. In patients with AA, maintaining adherence can be challenging due to the complex nature of their treatment regimens and the potential for side effects. Regular monitoring of HIV viral load, CD4+ counts, and hematologic parameters is essential for assessing the effectiveness of ART and making necessary adjustments. Supportive care and patient education on the importance of adherence can help improve treatment outcomes.[40] Advances in ART, including the development of new drug classes and formulations, hold promise for improving outcomes in patients with AA and HIV. Long-acting injectable ART options, which offer fewer dosing requirements, may be beneficial for improving adherence and managing complex regimens. Research into novel antiretroviral agents with reduced bone marrow toxicity and the exploration of combination therapies that minimize drug interactions are important areas for future investigation.[41] A patient-centered approach is essential in managing AA and HIV. Individualizing ART regimens based on patient-specific factors, including the severity of AA, comorbidities, and treatment goals, can enhance therapeutic outcomes. Collaboration between hematologists, infectious disease specialists, and other healthcare providers is crucial for developing comprehensive treatment plans that address both HIV and AA effectively.[42]

Immunologic Factors

Immunologic factors play a critical role in the development and progression of aplastic anemia (AA), particularly in the context of HIV infection. The interaction between immune system dysregulation and bone marrow failure can significantly impact the management and prognosis of AA.

1. Immune System Dysregulation in AA

Aplastic anemia is characterized by a failure of the bone marrow to produce adequate blood cells, which is often attributed to immune-mediated destruction of hematopoietic stem cells. In AA, the immune system mistakenly targets and destroys these cells, leading to hematologic deficiencies. This autoimmune aspect of AA can be exacerbated by HIV infection, which further disrupts normal immune function and contributes to the complexity of managing both conditions simultaneously.[43]

2. Role of T Cells

T cells, particularly CD8+ cytotoxic T cells, are implicated in the pathogenesis of AA. These cells can recognize and destroy bone marrow progenitor cells as part of an aberrant immune response. In HIV-infected individuals, the balance between different T cell subsets is altered, which may influence the severity and progression of AA. The presence of HIV can exacerbate T cell-mediated damage to hematopoietic cells, leading to more severe bone marrow failure and complicating treatment approaches.[44]

3. Cytokine Profile

Cytokines are signaling molecules that mediate immune responses and can significantly influence the pathogenesis of AA. In AA, elevated levels of pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), are often observed. These cytokines can contribute to bone marrow suppression and exacerbate the immune-mediated destruction of hematopoietic cells. HIV infection can further alter the cytokine profile, potentially aggravating the immune response and impacting AA progression.[45]

4. HIV-Induced Immunosuppression

HIV infection leads to a progressive decline in CD4+ T cell counts, which compromises the immune system's ability to regulate and respond to infections and other insults. This immunosuppression can impair the body's ability to mount an effective immune response against AA and may contribute to a more severe presentation of the disease. Additionally, HIV-related immunosuppression can affect the efficacy of treatments aimed at modulating the immune system in AA.[46]

5. Autoantibody Production

Autoantibodies targeting hematopoietic cells or bone marrow components are often detected in patients with AA. These autoantibodies contribute to the autoimmune destruction of bone marrow progenitor cells. In the context of HIV infection, the development and persistence of these autoantibodies may be influenced by the underlying immune dysfunction associated with the virus. Monitoring autoantibody levels can provide insights into the immune-mediated mechanisms driving AA and inform therapeutic strategies.[47]

6. Impact of Antiretroviral Therapy (ART)

ART has significant effects on immune function and can influence the course of AA. Certain ART drugs may have immunomodulatory effects that impact immune-mediated damage to bone marrow cells. For instance, ART may help restore immune function by increasing CD4+ T cell counts and reducing viral load, potentially mitigating some of the immune dysregulation associated with HIV. However, the choice of ART regimen must be carefully considered to avoid exacerbating bone marrow suppression.[48]

7. Bone Marrow Microenvironment

The bone marrow microenvironment plays a crucial role in hematopoiesis and immune regulation. In AA, the interaction between immune cells and the bone marrow stroma can impact the survival and function of hematopoietic stem cells. HIV infection can alter this microenvironment by introducing inflammatory factors and disrupting normal cell signaling. Understanding these changes is essential for developing targeted therapies that address both immune dysfunction and bone marrow failure.[49]

Presence of Comorbidities

The presence of comorbidities in patients with aplastic anemia (AA) and HIV infection can significantly influence the management and outcomes of both conditions. Comorbidities can complicate the clinical picture, impact treatment choices, and affect overall patient prognosis. Understanding how these comorbidities interact with AA and HIV is crucial for providing comprehensive care and optimizing treatment strategies.

1. HIV-Associated Comorbidities

HIV infection is commonly associated with a range of comorbidities that can affect patients with AA. These include:

- **Opportunistic Infections:** HIV increases susceptibility to opportunistic infections due to immunosuppression. Common infections such as Pneumocystis jirovecii pneumonia (PCP), tuberculosis (TB), and cytomegalovirus (CMV) can complicate the management of AA and exacerbate bone marrow suppression. Prophylactic and therapeutic strategies for these infections must be carefully managed to avoid further deterioration of hematologic parameters.[49]
- **HIV-Associated Malignancies:** Patients with HIV are at increased risk for certain malignancies, such as Kaposi's sarcoma, non-Hodgkin lymphoma, and invasive cervical cancer. The presence of these malignancies can complicate the diagnosis and treatment of AA, as they may require specific therapeutic interventions that impact bone marrow function.[50]
- **Metabolic Disorders:** HIV infection and its treatment can lead to metabolic disorders, such as insulin resistance, dyslipidemia, and osteoporosis. These conditions can complicate the management of AA by introducing additional health challenges and influencing the choice of treatments.

2. Hematologic Comorbidities

Patients with AA may also present with other hematologic comorbidities that affect their overall health and treatment options:

- **Myelodysplastic Syndromes (MDS):** MDS can present with similar clinical features to AA and may coexist with or mimic AA. Differentiating between these conditions is

essential for appropriate treatment, as MDS often requires different therapeutic approaches compared to AA.

- **Leukemia:** The risk of developing acute leukemia is higher in patients with AA. If leukemia is present, it necessitates a different treatment strategy, which may include chemotherapy or hematopoietic stem cell transplantation (HSCT), impacting the management of AA.
- **Sickle Cell Disease:** In regions where sickle cell disease is prevalent, patients with AA may also have this condition, which can complicate the management of anemia and increase the risk of vaso-occlusive crises. Treatment plans must address both conditions to optimize patient outcomes.

3. Autoimmune Disorders

Autoimmune disorders can complicate both AA and HIV management. Conditions such as systemic lupus erythematosus (SLE), rheumatoid arthritis, or vasculitis can exacerbate bone marrow failure and complicate treatment. The presence of these disorders may necessitate the use of immunosuppressive therapies, which can have additive effects on bone marrow suppression and increase the risk of infections.[51]

4. Chronic Kidney Disease

Chronic kidney disease (CKD) can impact hematologic parameters and complicate the management of AA. Kidney dysfunction can lead to reduced erythropoietin production, exacerbating anemia. Additionally, CKD can influence the metabolism and clearance of medications used to treat AA and HIV, requiring careful dose adjustments and monitoring.

5. Cardiovascular Disease

Cardiovascular disease (CVD) is a significant concern in HIV-infected patients, particularly those on long-term ART, which can contribute to cardiovascular risk. The presence of CVD can complicate the management of AA by increasing the risk of bleeding, thromboembolic events, and affecting overall treatment tolerability. Managing CVD alongside AA requires a multidisciplinary approach to balance cardiovascular health and hematologic needs.

6. Liver Disease

Liver disease, including chronic hepatitis B or C, is a common comorbidity in HIV-infected patients and can impact both AA and HIV management. Liver dysfunction can affect drug metabolism, leading to altered pharmacokinetics of ART and medications used to manage AA. It can also complicate the management of bleeding risks and necessitate adjustments in treatment regimens.[52]

7. Mental Health Disorders

Mental health disorders, such as depression and anxiety, are prevalent among patients with chronic illnesses, including AA and HIV. These conditions can impact treatment adherence, overall well-being, and quality of life. Addressing mental health issues is an integral part of managing AA and HIV, requiring psychological support and appropriate interventions.[53]

8. Nutritional Deficiencies

Nutritional deficiencies are common in patients with chronic diseases, including HIV and AA. Deficiencies in vitamins and minerals, such as folate, vitamin B12, and iron, can exacerbate anemia and impact overall health. Nutritional assessment and intervention are essential for optimizing hematologic parameters and supporting overall health in patients with AA and HIV.[53]

Genetic and Epigenetic Factors

Genetic and epigenetic factors play a significant role in the development and progression of aplastic anemia (AA), especially in the context of HIV infection. These factors can influence both the susceptibility to AA and the response to treatment.

1. Genetic Predisposition to Aplastic Anemia

Certain genetic factors can predispose individuals to AA. Genetic mutations and variations can impact hematopoiesis and immune regulation, increasing the risk of developing AA:

- **Inherited Genetic Syndromes:** Several inherited disorders are associated with AA, including Fanconi anemia, dyskeratosis congenita, and Diamond-Blackfan anemia. These genetic syndromes often involve mutations in genes related to DNA repair, telomere maintenance, and ribosome biogenesis, leading to bone marrow failure. Individuals with these syndromes may have an increased risk of developing AA, particularly in the context of HIV infection.
- **Genetic Variants:** Specific genetic variants can affect the risk of developing AA. For instance, polymorphisms in genes related to immune function, such as those encoding cytokines and immune receptors, may influence susceptibility to immune-mediated bone marrow failure. Genetic studies identifying such variants can provide insights into individual risk profiles and guide personalized treatment approaches.

2. Epigenetic Modifications

Epigenetic modifications, including DNA methylation, histone modifications, and non-coding RNA expression, can regulate gene expression without altering the underlying DNA sequence. These modifications play a crucial role in the development of AA:

- **DNA Methylation:** Abnormal DNA methylation patterns can lead to the silencing of genes involved in hematopoiesis and immune regulation. In AA, changes in DNA methylation

can contribute to the dysregulation of genes that support normal bone marrow function and immune homeostasis.

- **Histone Modifications:** Histone modifications, such as acetylation and methylation, influence chromatin structure and gene expression. Aberrant histone modifications can disrupt the normal regulation of genes involved in hematopoiesis and immune responses, contributing to the development of AA. Research into histone modifications in AA can provide insights into the mechanisms of disease progression and identify potential therapeutic strategies.
- **Non-Coding RNAs:** Non-coding RNAs, including microRNAs and long non-coding RNAs, play a role in regulating gene expression and cellular processes. Altered expression of these non-coding RNAs can impact hematopoiesis and immune function, contributing to the pathogenesis of AA. Identifying specific non-coding RNAs associated with AA can offer new avenues for diagnosis and treatment.

3. Interaction with HIV Infection

HIV infection can influence genetic and epigenetic factors, exacerbating the development and progression of AA:

- **HIV-Induced Genetic Changes:** HIV infection can induce genetic changes through mechanisms such as integration of viral DNA into the host genome. This integration can disrupt normal gene function and contribute to the development of AA. Additionally, the chronic inflammatory environment induced by HIV can impact gene expression and contribute to immune-mediated bone marrow failure.[54]
- **Epigenetic Alterations:** HIV infection is associated with global and gene-specific epigenetic changes. These alterations can affect the expression of genes involved in immune regulation, hematopoiesis, and viral replication. The interplay between HIV-induced epigenetic modifications and the development of AA is an area of active research, with potential implications for understanding disease mechanisms and developing targeted therapies.[54]

4. Genetic and Epigenetic Biomarkers

Identifying genetic and epigenetic biomarkers can enhance our understanding of AA and HIV-related complications:

- **Genetic Biomarkers:** Genetic biomarkers can provide insights into individual susceptibility to AA and inform personalized treatment strategies. For example, identifying specific genetic mutations associated with inherited AA syndromes can guide diagnosis and management.
- **Epigenetic Biomarkers:** Epigenetic biomarkers, such as DNA methylation patterns and non-coding RNA profiles, can help identify disease subtypes, predict disease progression,

and monitor treatment response. These biomarkers offer potential for non-invasive diagnostic and prognostic tools.

- **Table 1: Immunological Predictors of Treatment Response**

Immunological Factor	Description	Impact on Treatment Response
Immune Activation Markers	Elevated levels of cytokines like IL-6 and TNF-α	High levels correlate with worse treatment outcomes
CD4+ T-Cell Count	Key indicator of immune status in HIV patients	Higher CD4+ counts predict better treatment responses
Inflammatory Cytokines	Chronic inflammation due to HIV infection	Associated with increased morbidity and lower response rates

- **Table 2: Genetic Predictors of Treatment Response**

Genetic Predictor	Description	Impact on Treatment Response
Telomere Length	Indicator of cellular aging and genetic instability	Shorter telomeres linked to poorer response and higher relapse rates
HLA Typing	Compatibility of human leukocyte antigen in transplants	Well-matched HLA improves engraftment and treatment success
Genetic Mutations	Mutations in genes related to bone marrow function	Certain mutations may predispose to AA and influence treatment response

- **Table 3: Treatment-Related Predictors of Treatment Response**

Treatment Factor	Description	Impact on Treatment Response
Type of Immunosuppressive Therapy (IST)	Various regimens used in AA treatment	Certain regimens may be less effective in HIV-positive patients
Bone Marrow Transplantation (BMT)	Potential curative option for AA	Success depends on donor match and HIV control
Antiretroviral Therapy (ART)	Treatment for HIV to maintain viral suppression	Well-controlled HIV improves AA treatment outcomes

Table 1 shows Immunological Predictors of Treatment Response, Table 2 shows Genetic Predictors of Treatment Response and Table 3 shows Treatment-Related Predictors of Treatment Response (Provided by the authors).

Citation: Obeagu EI, Obeagu GU, Edoho SH. Predictive Factors for Response to Treatment in Aplastic Anemia with HIV: A Narrative Review**.** Elite Journal of Nursing and Health Science, 2024; 2(9):1-21

Treatment Adherence

Treatment adherence is a critical factor in managing aplastic anemia (AA) and HIV infection, particularly when the two conditions coexist. Adherence to prescribed therapies significantly impacts disease outcomes, treatment efficacy, and overall patient health.

1. Complexity of Treatment Regimens

Both AA and HIV require complex treatment regimens that can be challenging for patients to follow. AA treatment often involves immunosuppressive therapy, which may include medications like antithymocyte globulin (ATG), cyclosporine, or eltrombopag. HIV treatment, on the other hand, typically involves a regimen of highly active antiretroviral therapy (HAART) with multiple medications. The complexity of managing multiple medications with varying dosing schedules and potential side effects can be a significant barrier to adherence.[55]

2. Side Effects and Toxicity

The side effects and toxicity associated with AA and HIV treatments can affect adherence. For instance, immunosuppressive therapies used in AA can cause nausea, fatigue, and increased susceptibility to infections, which can impact the patient's quality of life and willingness to continue treatment. Similarly, HAART can have side effects such as gastrointestinal disturbances, lipid abnormalities, and potential drug interactions. Managing these side effects and finding effective strategies to mitigate them is crucial for improving adherence.[50]

3. Psychosocial Factors

Psychosocial factors play a significant role in treatment adherence. Patients with AA and HIV may face psychological challenges such as anxiety, depression, and stigma related to their conditions. The stress of managing a chronic illness, concerns about the long-term impact of medications, and social stigma can affect motivation and adherence to treatment regimens. Addressing these psychosocial issues through counseling, support groups, and mental health interventions can improve adherence and overall well-being.[52]

4. Health Literacy and Education

Health literacy and education are crucial for ensuring that patients understand their treatment regimens and the importance of adherence. Patients with a better understanding of their conditions, the rationale behind their treatments, and the potential consequences of non-adherence are more likely to adhere to their regimens. Providing clear, accessible information about AA and HIV, as well as practical advice on managing medications, can enhance patient understanding and adherence.[53]

5. Access to Healthcare and Medication

Access to healthcare and medications is another important factor influencing adherence. Patients may face barriers such as financial constraints, lack of health insurance, or difficulties accessing medications. These barriers can lead to interruptions in treatment and reduced adherence. Addressing these issues through financial assistance programs, patient assistance programs, and improved healthcare access can help ensure that patients receive their prescribed treatments consistently.[54]

6. Patient-Provider Communication

Effective communication between patients and healthcare providers is essential for promoting adherence. Providers need to engage with patients in a supportive and collaborative manner, addressing any concerns or barriers to adherence. Regular follow-up appointments, clear communication about treatment goals, and addressing any issues related to medication side effects or drug interactions can enhance adherence and patient satisfaction.[55]

7. Adherence Monitoring and Support

Monitoring adherence and providing ongoing support can help identify and address issues early. Tools such as medication adherence apps, pill organizers, and regular adherence assessments can help patients stay on track with their treatments. Additionally, healthcare providers can offer reminders, educational materials, and motivational support to reinforce the importance of adherence.

8. Personalized Adherence Strategies

Developing personalized adherence strategies tailored to individual patients' needs and circumstances can improve outcomes. This may involve adjusting treatment regimens to minimize side effects, providing targeted educational resources, and offering additional support based on the patient's specific challenges and preferences. Personalizing adherence strategies ensures that treatment plans are feasible and aligned with the patient's lifestyle and needs.

Conclusion

The management of aplastic anemia (AA) in the context of HIV infection presents a multifaceted challenge, influenced by a range of factors including genetic predispositions, epigenetic modifications, comorbidities, and the complexity of treatment regimens. Both AA and HIV require careful coordination of therapies, ongoing monitoring, and individualized care to optimize patient outcomes. Genetic and epigenetic factors play a pivotal role in the development and progression of AA, influencing susceptibility to the condition and the response to treatment. Understanding these factors provides valuable insights into the mechanisms underlying AA and can guide the development of targeted therapies. Similarly, the presence of comorbidities—such as opportunistic infections, malignancies, metabolic disorders, and autoimmune conditions—can significantly

impact the management of AA and HIV, requiring a comprehensive and multidisciplinary approach to address these complexities effectively.

References

1. Miano M, Dufour C. The diagnosis and treatment of aplastic anemia: a review. International journal of hematology. 2015; 101:527-535.
2. Obeagu EI, Kanu SN. Role of Immune Dysregulation in Aplastic Anemia Pathogenesis in HIV. Elite Journal of Health Science. 2024;2(9):112-28.
3. Obeagu EI. Immunological Insights into Aplastic Anemia within the Context of HIV: Unraveling the Complex Interplay. Elite Journal of Health Science. 2023;1(1):14-24.
4. Ndlovu Z, Burton R, Stewart R, Bygrave H, Roberts T, Fajardo E, Mataka A, Szumilin E, Kerschberger B, Van Cutsem G, Ellman T. Framework for the implementation of advanced HIV disease diagnostics in sub-Saharan Africa: programmatic perspectives. The Lancet HIV. 2020;7(7): e514-520.
5. Bandera A, Taramasso L, Bozzi G, Muscatello A, Robinson JA, Burdo TH, Gori A. HIV-associated neurocognitive impairment in the modern ART era: are we close to discovering reliable biomarkers in the setting of virological suppression? Frontiers in aging neuroscience. 2019; 11:187.
6. Ji Y, Lu H. Malignancies in HIV-infected and AIDS patients. Infectious Agents Associated Cancers: Epidemiology and Molecular Biology. 2017:167-179.
7. Wlodarski MW, Gondek LP, Nearman ZP, Plasilova M, Kalaycio M, Hsi ED, Maciejewski JP. Molecular strategies for detection and quantitation of clonal cytotoxic T-cell responses in aplastic anemia and myelodysplastic syndrome. Blood. 2006;108(8):2632-2641.
8. Borges-Almeida E, Milanez HM, Vilela MM, Cunha FG, Abramczuk BM, Reis-Alves SC, Metze K, Lorand-Metze I. The impact of maternal HIV infection on cord blood lymphocyte subsets and cytokine profile in exposed non-infected newborns. BMC infectious diseases. 2011; 11:1-1.
9. Obeagu EI. Immunological Insights into Aplastic Anemia within the Context of HIV: Unraveling the Complex Interplay. Elite Journal of Health Science. 2023;1(1):14-24.
10. Obeagu EI, Akinleye CA. A Review on the Clinical Manifestations and Complications of Aplastic Anemia in HIV. Elite Journal of Public Health. 2024;2(8):18-30.
11. Obeagu EI, Iheanacho MC. Aplastic Anemia in HIV: Role of Hematopoietic Cytokines and Growth Factors. Elite Journal of Laboratory Medicine. 2024;2(8):42-56.
12. Swain SL, McKinstry KK, Strutt TM. Expanding roles for CD4+ T cells in immunity to viruses. Nature Reviews Immunology. 2012;12(2):136-148.
13. Kany S, Vollrath JT, Relja B. Cytokines in inflammatory disease. International journal of molecular sciences. 2019;20(23):6008.
14. Li JP, Zheng CL, Han ZC. Abnormal immunity and stem/progenitor cells in acquired aplastic anemia. Critical reviews in oncology/hematology. 2010;75(2):79-93.

15. Jahandideh B, Derakhshani M, Abbaszadeh H, Movassaghpour AA, Mehdizadeh A, Talebi M, Yousefi M. The pro-Inflammatory cytokines effects on mobilization, self-renewal and differentiation of hematopoietic stem cells. Human Immunology. 2020;81(5):206-217.
16. Alexaki A, Wigdahl B. HIV-1 infection of bone marrow hematopoietic progenitor cells and their role in trafficking and viral dissemination. PLoS pathogens. 2008;4(12): e1000215.
17. Koka PS, Reddy ST. Cytopenias in HIV infection: mechanisms and alleviation of hematopoietic inhibition. Current HIV research. 2004;2(3):275-82.
18. Obeagu EI. Aplastic Anemia and HIV: The Role of Inflammatory Cytokines. Elite Journal of Laboratory Medicine. 2024;2(8):62-77.
19. Chauvin M, Sauce D. Mechanisms of immune aging in HIV. Clinical Science. 2022;136(1):61-80.
20. Pascutti MF, Erkelens MN, Nolte MA. Impact of viral infections on hematopoiesis: from beneficial to detrimental effects on bone marrow output. Frontiers in immunology. 2016; 7:364.
21. Goga Y. Haematological manifestations of HIV infection. HIV Infection in Children and Adolescents. 2020:115-129.
22. Sundermann EE, Hussain MA, Moore DJ, Horvath S, Lin DT, Kobor MS, Levine A, HNRP Group. Inflammation-related genes are associated with epigenetic aging in HIV. Journal of neurovirology. 2019; 25:853-865.
23. Obeagu EI, Kanu SN. Understanding the Genetic Susceptibility to Aplastic Anemia in HIV. Elite Journal of Laboratory Medicine. 2024;2(8):1-6.
24. Obeagu EI, Iheanacho MC. Genetic Factors Influencing Aplastic Anemia in the Context of HIV. Elite Journal of Health Science. 2024;2(9):143-55.
25. Feinstein MJ, Hsue PY, Benjamin LA, Bloomfield GS, Currier JS, Freiberg MS, Grinspoon SK, Levin J, Longenecker CT, Post WS, American Heart Association Prevention Science Committee of the Council on Epidemiology and Prevention and Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; and Stroke Council. Characteristics, prevention, and management of cardiovascular disease in people living with HIV: a scientific statement from the American Heart Association. Circulation. 2019;140(2): e98-124.
26. You X, Yang Q, Yan K, Wang SR, Huang RR, Wang SQ, Gao CY, Li L, Lian ZX. Multi-omics profiling identifies pathways associated with CD8+ T-cell activation in severe aplastic anemia. Frontiers in Genetics. 2022; 12:790990.
27. Omosigho PO, Ilesanmi AO, Asonye LN. Gender disparity in the reticulocyte count of HIV-positive patients on HAART management in Ilorin. J Clin Exp Hematol. 2024;3(1):22-28.
28. Marchionatti A, Parisi MM. Anemia and thrombocytopenia in people living with HIV/AIDS: a narrative literature review. International Health. 2021;13(2):98-109.
29. Chetty C, Musekwa E, Chapanduka ZC. The value of bone marrow examinations performed in the investigation of HIV infected patients with cytopenias. International Journal of Laboratory Hematology. 2023;45(4):553-561.

Citation: Obeagu EI, Obeagu GU, Edoho SH. Predictive Factors for Response to Treatment in Aplastic Anemia with HIV: A Narrative Review**.** Elite Journal of Nursing and Health Science, 2024; 2(9):1-21

30. Kontoghiorghes GJ. Drug Selection and Posology, Optimal Therapies and Risk/Benefit Assessment in Medicine: The Paradigm of Iron-Chelating Drugs. International Journal of Molecular Sciences. 2023;24(23):16749.
31. Redig AJ, Berliner N. Pathogenesis and clinical implications of HIV-related anemia in 2013. Hematology 2013, the American Society of Hematology Education Program Book. 2013;2013(1):377-81.
32. Lichtfuss GF, Hoy J, Rajasuriar R, Kramski M, Crowe SM, Lewin SR. Biomarkers of immune dysfunction following combination antiretroviral therapy for HIV infection. Biomarkers in medicine. 2011;5(2):171-186.
33. Bandera A, Taramasso L, Bozzi G, Muscatello A, Robinson JA, Burdo TH, Gori A. HIV-associated neurocognitive impairment in the modern ART era: are we close to discovering reliable biomarkers in the setting of virological suppression? Frontiers in aging neuroscience. 2019; 11:187.
34. Maciejewski JP, Selleri C, Sato T, Anderson S, Young NS. Increased expression of Fas antigen on bone marrow CD34+ cells of patients with aplastic anaemia. British journal of haematology. 1995;91(1):245-252.
35. Scadden DT. Hematologic disorders and growth factor support in HIV infection. Hematology/oncology clinics of North America. 1996;10(5):1149-1161.
36. Shapaka JT. Laboratory findings that occur in Klebsiella pneumoniae blood stream infection in HIV-infected children compared to HIV uninfected children, at a South African children's hospital, Cape Town, 2006–2011: a nested-descriptive cross-sectional study.
37. McInally S, Wall K, Yu T, Tirouvanziam R, Kilembe W, Gilmour J, Allen SA, Hunter E. Elevated levels of inflammatory plasma biomarkers are associated with risk of HIV infection. Retrovirology. 2021; 18:1-1.
38. Gonzalez SM, Taborda NA, Rugeles MT. Role of different subpopulations of CD8+ T cells during HIV exposure and infection. Frontiers in immunology. 2017; 8:936.
39. García-Calvo X, Bolao F, Sanvisens A, Zuluaga P, Tor J, Muga R, Fuster D. Significance of markers of monocyte activation (CD163 and sCD14) and inflammation (IL-6) in patients admitted for alcohol use disorder treatment. Alcoholism: Clinical and Experimental Research. 2020;44(1):152-158.
40. Abbas M, Steffens S, Bellut M, Becker JU, Großhennig A, Eggers H, Wegener G, Kuczyk MA, Kreipe HH, Grünwald V, Schrader AJ. Do programmed death 1 (PD-1) and its ligand (PD-L1) play a role in patients with non-clear cell renal cell carcinoma? Medical Oncology. 2016; 33:1-7.
41. Ouyang J, Yan J, Zhou X, Isnard S, Harypursat V, Cui H, Routy JP, Chen Y. Relevance of biomarkers indicating gut damage and microbial translocation in people living with HIV. Frontiers in Immunology. 2023; 14:1173956.
42. Rallón N, García M, García-Samaniego J, Rodríguez N, Cabello A, Restrepo C, Álvarez B, García R, Górgolas M, Benito JM. HCV coinfection contributes to HIV pathogenesis by increasing immune exhaustion in CD8 T-cells. PLoS One. 2017;12(3): e0173943.

43. Catania A, Manfredi MG, Airaghi L, Vivirito MC, Capetti A, Milazzo F, Lipton JM, Zanussi C. Plasma concentration of cytokine antagonists in patients with HIV infection. Neuroimmunomodulation. 1994;1(1):42-9.
44. Crisà E, Boggione P, Nicolosi M, Mahmoud AM, Al Essa W, Awikeh B, Aspesi A, Andorno A, Boldorini R, Dianzani I, Gaidano G. Genetic predisposition to myelodysplastic syndromes: a challenge for adult hematologists. International Journal of Molecular Sciences. 2021;22(5):2525.
45. Dye CK, Corley MJ, Li D, Khadka VS, Mitchell BI, Sultana R, Lum-Jones A, Shikuma CM, Ndhlovu LC, Maunakea AK. Comparative DNA methylomic analyses reveal potential origins of novel epigenetic biomarkers of insulin resistance in monocytes from virally suppressed HIV-infected adults. Clinical Epigenetics. 2019; 11:1-9.
46. Fattizzo B, Giannotta JA, Barcellini W. Mesenchymal stem cells in aplastic anemia and myelodysplastic syndromes: the “seed and soil” crosstalk. International journal of molecular sciences. 2020;21(15):5438.
47. Dharan NJ, Yeh P, Bloch M, Yeung MM, Baker D, Guinto J, Roth N, Ftouni S, Ognenovska K, Smith D, Hoy JF. HIV is associated with an increased risk of age-related clonal hematopoiesis among older adults. Nature medicine. 2021;27(6):1006-1011.
48. Donnelly MR, Ciborowski P. Proteomics, biomarkers, and HIV-1: A current perspective. PROTEOMICS–Clinical Applications. 2016;10(2):110-25.
49. Patters BJ, Kumar S. The role of exosomal transport of viral agents in persistent HIV pathogenesis. Retrovirology. 2018;15(1):79.
50. Borjabad A, Brooks AI, Volsky DJ. Gene expression profiles of HIV-1-infected glia and brain: toward better understanding of the role of astrocytes in HIV-1-associated neurocognitive disorders. Journal of Neuroimmune Pharmacology. 2010; 5:44-62.
51. Liberal R, Mieli-Vergani G, Vergani D. Clinical significance of autoantibodies in autoimmune hepatitis. Journal of autoimmunity. 2013; 46:17-24.
52. Votavova H, Belickova M. Hypoplastic myelodysplastic syndrome and acquired aplastic anemia: Immune-mediated bone marrow failure syndromes. International journal of oncology. 2021;60(1):7.
53. Malone ER, Oliva M, Sabatini PJ, Stockley TL, Siu LL. Molecular profiling for precision cancer therapies. Genome medicine. 2020; 12:1-9.
54. Lee EY, Kulkarni RP. Circulating biomarkers predictive of tumor response to cancer immunotherapy. Expert review of molecular diagnostics. 2019;19(10):895-904.
55. Narita A, Kojima S. Biomarkers for predicting clinical response to immunosuppressive therapy in aplastic anemia. International Journal of Hematology. 2016; 104:153-158.